Trial reportFrontiers in medicine2026
Changes in MoCA scores with sequential administration of Trikatu Cūrṇa and Brahmi Ghṛta in mild cognitive impairment: an exploratory single-arm clinical study.
Trial report in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Mild cognitive impairment (MCI) is an intermediate clinical state between normal cognitive aging and dementia. MCI can impair complex daily activities and social functioning. Ayurveda recognizes age-related changes (Jarā) as a natural phenomenon; however, pathological cognitive decline is considered when influenced by doṣa-vaiṣamya. Descriptions of Buddhi-bhraṁśa and Smṛti-bhraṁśa can be correlated with cognitive decline. Current pharmacological and non-pharmacological approaches show variable outcomes, highlighting the need for supportive and integrative strategies. Methods: The single-arm, open-label clinical study evaluated 24 participants diagnosed with mild neurocognitive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. The patients were administered Trikatu Cūrṇa 3 g twice daily, after food, for 7 days, followed by Brahmi Ghṛta 5 mL twice daily with milk as Anupāna, after food, for 90 days. Out of the 27 enrolled participants, 24 completed the study and 3 dropped out. Cognitive assessment was carried out using the Montreal Cognitive Assessment (MoCA) Scale. This study is registered in the Clinical Trial Registry of India under CTRI/2024/07/070223 before enrolment of the first participant. Results: Post-intervention assessment demonstrated a statistically significant improvement in overall cognitive scores compared to baseline ( Discussion: Trikatu Cūrṇa, through its Dīpana-Pācana action, may support Agni and help in Āma reduction, thereby improving metabolic efficiency and drug absorption. Brahmi ( Clinical trial registration: https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=MTEwODI2&Enc=&userName=.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.